{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:23:43Z","timestamp":1788920623924,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:00:00Z","timestamp":1515974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:00:00Z","timestamp":1515974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Olanzapine is a widely prescribed antipsychotic drug. While effective in reducing psychoses, treatment with olanzapine causes rapid increases in blood glucose. We wanted to determine if a single bout of exercise, immediately prior to treatment, would attenuate the olanzapine-induced rise in blood glucose and if this occurred in an IL-6 dependent manner. We found that exhaustive, but not moderate exercise, immediately prior to treatment, prevented olanzapine-induced hyperglycemia and this occurred in parallel with increases in serum IL-6. To determine if IL-6 was involved in the mechanisms through which exhaustive exercise protected against olanzapine-induced hyperglycemia several additional experiments were completed. Treatment with IL-6 (3 ng\/g bw, IP) alone did not protect against olanzapine-induced increases in blood glucose. The protective effects of exhaustive exercise against olanzapine-induced increases in blood glucose were intact in whole body IL-6 knockout mice. Similarly, treating mice with an IL-6 neutralizing antibody prior to exhaustive exercise did not negate the protective effect of exercise against olanzapine-induced hyperglycemia. Our findings provide evidence that a single bout of exhaustive exercise protects against acute olanzapine-induced hyperglycemia and that IL-6 is neither sufficient, nor required for exercise to protect against increases in blood glucose with olanzapine treatment.<\/jats:p>","DOI":"10.1038\/s41598-018-19260-x","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T16:42:07Z","timestamp":1515516127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Exercise Protects Against Olanzapine-Induced Hyperglycemia in Male C57BL\/6J Mice"],"prefix":"10.1038","volume":"8","author":[{"given":"Laura N.","family":"Castellani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem T.","family":"Peppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Miotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,15]]},"reference":[{"key":"19260_CR1","doi-asserted-by":"publisher","first-page":"E225","DOI":"10.9778\/cmajo.20140009","volume":"2","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim, T. & Gardner, D. M. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open 2, E225\u2013232, https:\/\/doi.org\/10.9778\/cmajo.20140009 (2014).","journal-title":"CMAJ Open"},{"key":"19260_CR2","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2011.1360","volume":"306","author":"AR Maher","year":"2011","unstructured":"Maher, A. R. et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306, 1359\u20131369, https:\/\/doi.org\/10.1001\/jama.2011.1360 (2011).","journal-title":"JAMA"},{"key":"19260_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari, R. M. et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375, 134\u2013142, https:\/\/doi.org\/10.1056\/NEJMoa1515725 (2016).","journal-title":"N Engl J Med"},{"key":"19260_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.4088\/JCP.08m04912gre","volume":"71","author":"RM Procyshyn","year":"2010","unstructured":"Procyshyn, R. M. et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 71, 566\u2013573, https:\/\/doi.org\/10.4088\/JCP.08m04912gre (2010).","journal-title":"J Clin Psychiatry"},{"key":"19260_CR5","doi-asserted-by":"crossref","unstructured":"American Diabetes, A., American Psychiatric, A., American Association of Clinical, E. & North American Association for the Study of, O. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65, 267\u2013272 (2004).","DOI":"10.4088\/JCP.v65n0219"},{"key":"19260_CR6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.4088\/JCP.v66n0414","volume":"66","author":"RN Bergman","year":"2005","unstructured":"Bergman, R. N. & Ader, M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 66, 504\u2013514 (2005).","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 1","key":"19260_CR7","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer, J. W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1), 1\u201393 (2005).","journal-title":"CNS Drugs"},{"key":"19260_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1192\/bjp.bp.109.076935","volume":"197","author":"LV Kessing","year":"2010","unstructured":"Kessing, L. V., Thomsen, A. F., Mogensen, U. B. & Andersen, P. K. Treatment with antipsychotics and the risk of diabetes in clinical practice. The British journal of psychiatry: the journal of mental science 197, 266\u2013271, https:\/\/doi.org\/10.1192\/bjp.bp.109.076935 (2010).","journal-title":"The British journal of psychiatry: the journal of mental science"},{"key":"19260_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/0269881107080215","volume":"21","author":"GP Reynolds","year":"2007","unstructured":"Reynolds, G. P. Schizophrenia, antipsychotics and metabolic disease. J Psychopharmacol 21, 355\u2013356, https:\/\/doi.org\/10.1177\/0269881107080215 (2007).","journal-title":"J Psychopharmacol"},{"key":"19260_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00006","volume":"119","author":"FX Pi-Sunyer","year":"1993","unstructured":"Pi-Sunyer, F. X. Medical hazards of obesity. Annals of internal medicine 119, 655\u2013660 (1993).","journal-title":"Annals of internal medicine"},{"key":"19260_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ejphar.2013.08.006","volume":"718","author":"M Ikegami","year":"2013","unstructured":"Ikegami, M. et al. Olanzapine induces glucose intolerance through the activation of AMPK in the mouse hypothalamus. Eur J Pharmacol 718, 376\u2013382, https:\/\/doi.org\/10.1016\/j.ejphar.2013.08.006 (2013).","journal-title":"Eur J Pharmacol"},{"key":"19260_CR12","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/dom.12148","volume":"15","author":"M Ikegami","year":"2013","unstructured":"Ikegami, M. et al. Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5\u2032-monophosphate-activated protein kinase. Diabetes Obes Metab 15, 1128\u20131135, https:\/\/doi.org\/10.1111\/dom.12148 (2013).","journal-title":"Diabetes Obes Metab"},{"key":"19260_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","volume":"108","author":"AF Chintoh","year":"2009","unstructured":"Chintoh, A. F. et al. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophrenia research 108, 127\u2013133, https:\/\/doi.org\/10.1016\/j.schres.2008.12.012 (2009).","journal-title":"Schizophrenia research"},{"key":"19260_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/01.jcp.0000237947.80764.d9","volume":"26","author":"CC Chiu","year":"2006","unstructured":"Chiu, C. C., Chen, K. P., Liu, H. C. & Lu, M. L. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. Journal of clinical psychopharmacology 26, 504\u2013507, https:\/\/doi.org\/10.1097\/01.jcp.0000237947.80764.d9 (2006).","journal-title":"Journal of clinical psychopharmacology"},{"key":"19260_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/JCP.0b013e31829e8333","volume":"33","author":"MK Hahn","year":"2013","unstructured":"Hahn, M. K. et al. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. Journal of clinical psychopharmacology 33, 740\u2013746, https:\/\/doi.org\/10.1097\/JCP.0b013e31829e8333 (2013).","journal-title":"Journal of clinical psychopharmacology"},{"key":"19260_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.npp.1301209","volume":"32","author":"KL Houseknecht","year":"2007","unstructured":"Houseknecht, K. L. et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 32, 289\u2013297, https:\/\/doi.org\/10.1038\/sj.npp.1301209 (2007).","journal-title":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology"},{"key":"19260_CR17","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.2337\/db10-0449","volume":"59","author":"PJ Martins","year":"2010","unstructured":"Martins, P. J., Haas, M. & Obici, S. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 59, 2418\u20132425, https:\/\/doi.org\/10.2337\/db10-0449 (2010).","journal-title":"Diabetes"},{"key":"19260_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.2337\/diabetes.54.3.862","volume":"54","author":"M Ader","year":"2005","unstructured":"Ader, M. et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54, 862\u2013871 (2005).","journal-title":"Diabetes"},{"key":"19260_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1247\/csf.13012","volume":"38","author":"R Ozasa","year":"2013","unstructured":"Ozasa, R. et al. The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic beta cells by blocking PERK-mediated translational attenuation. Cell Struct Funct 38, 183\u2013195 (2013).","journal-title":"Cell Struct Funct"},{"key":"19260_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s40618-014-0093-6","volume":"37","author":"S Shu","year":"2014","unstructured":"Shu, S. et al. Subchronic olanzapine treatment decreases the expression of pancreatic glucose transporter 2 in rat pancreatic beta cells. J Endocrinol Invest 37, 667\u2013673, https:\/\/doi.org\/10.1007\/s40618-014-0093-6 (2014).","journal-title":"J Endocrinol Invest"},{"key":"19260_CR21","doi-asserted-by":"publisher","first-page":"e43244","DOI":"10.1371\/journal.pone.0043244","volume":"7","author":"EM Girault","year":"2012","unstructured":"Girault, E. M. et al. Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance. PLoS One 7, e43244, https:\/\/doi.org\/10.1371\/journal.pone.0043244 (2012).","journal-title":"PLoS One"},{"key":"19260_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1503\/jpn.110140","volume":"37","author":"HN Boyda","year":"2012","unstructured":"Boyda, H. N. et al. Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. Journal of psychiatry & neuroscience: JPN 37, 407\u2013415, https:\/\/doi.org\/10.1503\/jpn.110140 (2012).","journal-title":"Journal of psychiatry & neuroscience: JPN"},{"key":"19260_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1530\/JOE-15-0074","volume":"227","author":"GJ Remington","year":"2015","unstructured":"Remington, G. J. et al. Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. J Endocrinol 227, 71\u201381, https:\/\/doi.org\/10.1530\/JOE-15-0074 (2015).","journal-title":"J Endocrinol"},{"key":"19260_CR24","doi-asserted-by":"publisher","unstructured":"Venkatasubramanian, G., Arasappa, R., Rao, N. P., Behere, R. V. & Gangadhar, B. N. Adjuvant metformin worsens psychosis in schizophrenia: a case report. Primary care companion to the Journal of clinical psychiatry 12, https:\/\/doi.org\/10.4088\/PCC.09l00801yel (2010).","DOI":"10.4088\/PCC.09l00801yel"},{"key":"19260_CR25","doi-asserted-by":"crossref","unstructured":"Ahmadian, M. et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med 19, 557\u2013566, doi:nm.3159 (2013).","DOI":"10.1038\/nm.3159"},{"key":"19260_CR26","doi-asserted-by":"publisher","first-page":"E453","DOI":"10.1152\/ajpendo.00463.2002","volume":"284","author":"JO Holloszy","year":"2003","unstructured":"Holloszy, J. O. A forty-year memoir of research on the regulation of glucose transport into muscle. Am J Physiol Endocrinol Metab 284, E453\u2013467, https:\/\/doi.org\/10.1152\/ajpendo.00463.2002 (2003).","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"19260_CR27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1172\/JCI110517","volume":"69","author":"EA Richter","year":"1982","unstructured":"Richter, E. A., Garetto, L. P., Goodman, M. N. & Ruderman, N. B. Muscle glucose metabolism following exercise in the rat: increased sensitivity to insulin. J Clin Invest 69, 785\u2013793 (1982).","journal-title":"J Clin Invest"},{"key":"19260_CR28","doi-asserted-by":"crossref","unstructured":"Ellingsgaard, H. et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17, 1481\u20131489, doi:nm.2513 (2011).","DOI":"10.1038\/nm.2513"},{"key":"19260_CR29","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2337\/diabetes.53.7.1643","volume":"53","author":"MA Febbraio","year":"2004","unstructured":"Febbraio, M. A., Hiscock, N., Sacchetti, M., Fischer, C. P. & Pedersen, B. K. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53, 1643\u20131648 (2004).","journal-title":"Diabetes"},{"key":"19260_CR30","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1113\/expphysiol.2012.065508","volume":"97","author":"A Benrick","year":"2012","unstructured":"Benrick, A., Wallenius, V. & Asterholm, I. W. Interleukin-6 mediates exercise-induced increase in insulin sensitivity in mice. Exp Physiol 97, 1224\u20131235, https:\/\/doi.org\/10.1113\/expphysiol.2012.065508 (2012).","journal-title":"Exp Physiol"},{"key":"19260_CR31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.bbrc.2016.03.159","volume":"473","author":"S Ikeda","year":"2016","unstructured":"Ikeda, S. et al. Exercise-induced increase in IL-6 level enhances GLUT4 expression and insulin sensitivity in mouse skeletal muscle. Biochem Biophys Res Commun 473, 947\u2013952, https:\/\/doi.org\/10.1016\/j.bbrc.2016.03.159 (2016).","journal-title":"Biochem Biophys Res Commun"},{"key":"19260_CR32","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1152\/japplphysiol.00551.2015","volume":"119","author":"L Castellani","year":"2015","unstructured":"Castellani, L. et al. Exercise-mediated IL-6 signaling occurs independent of inflammation and is amplified by training in mouse adipose tissue. J Appl Physiol (1985) 119, 1347\u20131354, https:\/\/doi.org\/10.1152\/japplphysiol.00551.2015 (2015).","journal-title":"J Appl Physiol (1985)"},{"key":"19260_CR33","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1152\/physrev.90100.2007","volume":"88","author":"BK Pedersen","year":"2008","unstructured":"Pedersen, B. K. & Febbraio, M. A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88, 1379\u20131406, https:\/\/doi.org\/10.1152\/physrev.90100.2007 (2008).","journal-title":"Physiol Rev"},{"key":"19260_CR34","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1096\/fj.01-0507fje","volume":"15","author":"C Keller","year":"2001","unstructured":"Keller, C. et al. Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 15, 2748\u20132750, https:\/\/doi.org\/10.1096\/fj.01-0507fje (2001).","journal-title":"FASEB J"},{"key":"19260_CR35","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00533.2013","author":"S Wueest","year":"2014","unstructured":"Wueest, S. et al. Interleukin-6 contributes to early fasting-induced free fatty acid mobilization in mice. Am J Physiol Regul Integr Comp Physiol. https:\/\/doi.org\/10.1152\/ajpregu.00533.2013 (2014).","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"19260_CR36","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.neuropharm.2011.02.019","volume":"62","author":"HN Boyda","year":"2012","unstructured":"Boyda, H. N. et al. Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology 62, 1391\u20131400, https:\/\/doi.org\/10.1016\/j.neuropharm.2011.02.019 (2012).","journal-title":"Neuropharmacology"},{"key":"19260_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1017\/S1461145713000795","volume":"17","author":"HN Boyda","year":"2014","unstructured":"Boyda, H. N. et al. Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats. The international journal of neuropsychopharmacology \/ official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 17, 77\u201390, https:\/\/doi.org\/10.1017\/S1461145713000795 (2014).","journal-title":"The international journal of neuropsychopharmacology \/ official scientific journal of the Collegium Internationale Neuropsychopharmacologicum"},{"key":"19260_CR38","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/17461391.2013.862871","volume":"14","author":"I Giannopoulou","year":"2014","unstructured":"Giannopoulou, I., Botonis, P., Kostara, C. & Skouroliakou, M. Diet and exercise effects on aerobic fitness and body composition in seriously mentally ill adults. Eur J Sport Sci 14, 620\u2013627, https:\/\/doi.org\/10.1080\/17461391.2013.862871 (2014).","journal-title":"Eur J Sport Sci"},{"key":"19260_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1176\/appi.ajp.2014.14020173","volume":"172","author":"CA Green","year":"2015","unstructured":"Green, C. A. et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. The American journal of psychiatry 172, 71\u201381, https:\/\/doi.org\/10.1176\/appi.ajp.2014.14020173 (2015).","journal-title":"The American journal of psychiatry"},{"key":"19260_CR40","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00424-013-1399-5","volume":"466","author":"RS Bienso","year":"2014","unstructured":"Bienso, R. S., Knudsen, J. G., Brandt, N., Pedersen, P. A. & Pilegaard, H. Effects of IL-6 on pyruvate dehydrogenase regulation in mouse skeletal muscle. Pflugers Arch 466, 1647\u20131657, https:\/\/doi.org\/10.1007\/s00424-013-1399-5 (2014).","journal-title":"Pflugers Arch"},{"key":"19260_CR41","doi-asserted-by":"publisher","first-page":"e84910","DOI":"10.1371\/journal.pone.0084910","volume":"9","author":"JG Knudsen","year":"2014","unstructured":"Knudsen, J. G. et al. Role of IL-6 in exercise training- and cold-induced UCP1 expression in subcutaneous white adipose tissue. PLoS One 9, e84910, https:\/\/doi.org\/10.1371\/journal.pone.0084910 (2014).","journal-title":"PLoS One"},{"key":"19260_CR42","doi-asserted-by":"crossref","unstructured":"O\u2019Neill, H. M. et al. AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. Proc Natl Acad Sci USA 108, 16092\u201316097, doi:1105062108 (2011).","DOI":"10.1073\/pnas.1105062108"},{"key":"19260_CR43","doi-asserted-by":"publisher","first-page":"598","DOI":"10.2337\/db16-0530","volume":"66","author":"R Kjobsted","year":"2017","unstructured":"Kjobsted, R. et al. Enhanced Muscle Insulin Sensitivity After Contraction\/Exercise Is Mediated by AMPK. Diabetes 66, 598\u2013612, https:\/\/doi.org\/10.2337\/db16-0530 (2017).","journal-title":"Diabetes"},{"key":"19260_CR44","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.2337\/db14-0100","volume":"63","author":"F Kahles","year":"2014","unstructured":"Kahles, F. et al. GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes 63, 3221\u20133229, https:\/\/doi.org\/10.2337\/db14-0100 (2014).","journal-title":"Diabetes"},{"key":"19260_CR45","doi-asserted-by":"publisher","first-page":"E563","DOI":"10.1152\/ajpendo.00287.2014","volume":"307","author":"RE MacPherson","year":"2014","unstructured":"MacPherson, R. E., Castellani, L., Beaudoin, M. S. & Wright, D. C. Evidence for fatty acids mediating CL 316,243-induced reductions in blood glucose in mice. Am J Physiol Endocrinol Metab 307, E563\u2013570, https:\/\/doi.org\/10.1152\/ajpendo.00287.2014 (2014).","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"19260_CR46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.psyneuen.2017.05.005","volume":"82","author":"LN Castellani","year":"2017","unstructured":"Castellani, L. N. et al. Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia. Psychoneuroendocrinology 82, 38\u201345, https:\/\/doi.org\/10.1016\/j.psyneuen.2017.05.005 (2017).","journal-title":"Psychoneuroendocrinology"},{"key":"19260_CR47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.schres.2016.05.017","volume":"176","author":"B Stubbs","year":"2016","unstructured":"Stubbs, B. et al. How much physical activity do people with schizophrenia engage in? A systematic review, comparative meta-analysis and meta-regression. Schizophrenia research 176, 431\u2013440, https:\/\/doi.org\/10.1016\/j.schres.2016.05.017 (2016).","journal-title":"Schizophrenia research"},{"key":"19260_CR48","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cpr.2016.11.009","volume":"52","author":"M Cella","year":"2017","unstructured":"Cella, M., Preti, A., Edwards, C., Dow, T. & Wykes, T. Cognitive remediation for negative symptoms of schizophrenia: A network meta-analysis. Clin Psychol Rev 52, 43\u201351, https:\/\/doi.org\/10.1016\/j.cpr.2016.11.009 (2017).","journal-title":"Clin Psychol Rev"},{"key":"19260_CR49","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1017\/S0033291714003110","volume":"45","author":"J Firth","year":"2015","unstructured":"Firth, J., Cotter, J., Elliott, R., French, P. & Yung, A. R. A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med 45, 1343\u20131361, https:\/\/doi.org\/10.1017\/S0033291714003110 (2015).","journal-title":"Psychol Med"},{"key":"19260_CR50","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/368339a0","volume":"368","author":"M Kopf","year":"1994","unstructured":"Kopf, M. et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368, 339\u2013342, https:\/\/doi.org\/10.1038\/368339a0 (1994).","journal-title":"Nature"},{"key":"19260_CR51","unstructured":"O\u2019Neill, H. M. et al. Il-6 Is Not Essential for Exercise-Induced Increases in Glucose Uptake. J Appl Physiol, doi:japplphysiol.00946.2012 (2013)."},{"key":"19260_CR52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1124\/jpet.102.046987","volume":"305","author":"S Kapur","year":"2003","unstructured":"Kapur, S., VanderSpek, S. C., Brownlee, B. A. & Nobrega, J. N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305, 625\u2013631, https:\/\/doi.org\/10.1124\/jpet.102.046987 (2003).","journal-title":"J Pharmacol Exp Ther"},{"key":"19260_CR53","doi-asserted-by":"publisher","first-page":"R102","DOI":"10.1152\/ajpregu.00150.2013","volume":"306","author":"EA Herbst","year":"2014","unstructured":"Herbst, E. A. et al. Pyruvate dehydrogenase kinase-4 contributes to the recirculation of gluconeogenic precursors during postexercise glycogen recovery. Am J Physiol Regul Integr Comp Physiol 306, R102\u2013107, https:\/\/doi.org\/10.1152\/ajpregu.00150.2013 (2014).","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"19260_CR54","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1042\/BCJ20160373","volume":"473","author":"PM Miotto","year":"2016","unstructured":"Miotto, P. M. & Holloway, G. P. In the absence of phosphate shuttling, exercise reveals the in vivo importance of creatine-independent mitochondrial ADP transport. Biochem J 473, 2831\u20132843, https:\/\/doi.org\/10.1042\/BCJ20160373 (2016).","journal-title":"Biochem J"},{"key":"19260_CR55","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","volume":"150","author":"PK Smith","year":"1985","unstructured":"Smith, P. K. et al. Measurement of protein using bicinchoninic acid. Anal Biochem 150, 76\u201385 (1985).","journal-title":"Anal Biochem"},{"key":"19260_CR56","doi-asserted-by":"publisher","first-page":"R934","DOI":"10.1152\/ajpregu.00497.2015","volume":"310","author":"WT Peppler","year":"2016","unstructured":"Peppler, W. T., Anderson, Z. G., Sutton, C. D., Rector, R. S. & Wright, D. C. Voluntary wheel running attenuates lipopolysaccharide-induced liver inflammation in mice. Am J Physiol Regul Integr Comp Physiol 310, R934\u2013942, https:\/\/doi.org\/10.1152\/ajpregu.00497.2015 (2016).","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"19260_CR57","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408, https:\/\/doi.org\/10.1006\/meth.2001.1262 (2001).","journal-title":"Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19260-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19260-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19260-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:05:41Z","timestamp":1671584741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19260-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,15]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["19260"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-19260-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,15]]},"assertion":[{"value":"17 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"772"}}